Impel NeuroPharma Incorporated is developing therapies for patients suffering from central nervous system diseases. The company's pipeline includes TRUDHESA, an upper nasal formulation of dihydroergotamine for the treatment of migraines, INP105, an upper nasal formulation of olanzapine for the treatment of agitation and aggression in autism spectrum disorder, and INP107, an upper nasal formulation of Carbidopa/Levodopa. Impel NeuroPharma was incorporated in 2008 and is headquartered in Seattle, WA.
What is Impel Pharmaceuticals's quote symbol?
What is the 52 week high and low for Impel Pharmaceuticals (NASDAQ: IMPL)?
How much is Impel Pharmaceuticals stock worth today?
How much is Impel Pharmaceuticals's stock price per share?
What is Impel Pharmaceuticals's Market Cap?